Published Date: Feb-19
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report LAMEA Smart Insulin Pen Market, published by KBV research, the LAMEA Smart Insulin Pen Market would witness market growth of 11.9% CAGR during the forecast period (2018 – 2024).
The Brazil market would dominate the LAMEA Second Generation Pens Market by Country by 2024, growing at a CAGR of 11.7 % during the forecast period. The Argentina market is expected to witness a CAGR of 13.2% during (2018 - 2024). Additionally, The UAE market is expected to witness a CAGR of 11.1% during (2018 - 2024).
The Hospitals & Clinics market dominated the LAMEA Smart Insulin Pen Market by End User in 2017. The Ambulatory Surgical Centers market is expected to witness a CAGR of 12.3% during (2018 - 2024).
The Prefilled market dominated the UAE Smart Insulin Pen Market by Usability in 2017, and would achieve a market value of $1,057 Thousand by 2024. The Reusable market is expected to witness a CAGR of 11.2% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Companion Medical Inc., Digital Medics Ptd Ltd., Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co., Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Emperra GmbH E-Health Technologies, Jiangsu Delfu medical device Co. Ltd., Bigfoot biomedica.
LAMEA Smart Insulin Pen Market Segmentation
By End User
Unique Offerings from KBV Research